Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s stock price traded down 1.7% during mid-day trading on Thursday . The company traded as low as $0.55 and last traded at $0.59. 33,386 shares were traded during mid-day trading, an increase of 16% from the average session volume of 28,782 shares. The stock had previously closed at $0.60.
Humacyte Stock Down 1.7%
The business has a 50-day moving average of $0.43 and a 200-day moving average of $1.01.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
- Five stocks we like better than Humacyte
- 3 Monster Growth Stocks to Buy Now
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- How to Profit From Value Investing
- 3 Stocks Set to Double—And There’s Still Time to Buy
- Learn Technical Analysis Skills to Master the Stock Market
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
